(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between May 31 and June 4 was host to the Rapid Oral Abstract Session: Genitourinary Cancer - Prostate, Testicular, and Penile. Dr. Mark Linch presented results from the NEPTUNES (NCT03061539), a multi-centre two-cohort, biomarker-selected phase 2 trial evaluating Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) for metastatic prostate cancer with an immunogenic signature.
Dr. Linch initiated his presentation by addressing the limited responses observed with immune checkpoint inhibitor monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC) (1). This phenomenon is largely attributed to the prevalence of a "cold" tumor immune microenvironment. Anti-CTLA4 therapy has been found to induce T-cell infiltration in prostate cancer, but most importantly, the combination of anti-CTLA4 and anti-PD1 has demonstrated a signal of activity in unselected patients with mCRPC in the preliminary analysis of the CheckMate 650 Trial combining Nivolumab+ipilimumab (2). Moreover, up to 20% of patients with high-risk PCa have high tumor infiltrating lymphocytes (TILs), which have been shown, albeit inconsistently, to be prognostic in PCa. (3)
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with mHSPC
Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
